trending Market Intelligence /marketintelligence/en/news-insights/trending/r3gnqru8dcgcxsa-adu8nq2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Kazia Therapeutics raises A$3.4M to fund R&D activities

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Kazia Therapeutics raises A$3.4M to fund R&D activities

Kazia Therapeutics Ltd. secured additional funds worth A$3.4 million through an institutional placement of its 8.9 million new fully paid ordinary shares priced at 38 Australian cents apiece.

The transaction was led by WG Partners LLP, with participation from institutional, professional and sophisticated investors.

Additionally, the Sydney-based company will initiate a share purchase plan that allows its eligible existing shareholders to purchase new fully paid ordinary shares Oct. 23.

The placement does not require shareholder approval, the company added.

Kazia will use the proceeds to fund its research and development activities, which includes the further development of GDC-0084, a potential treatment of the most common and most aggressive form of brain cancer known as glioblastoma multiforme, and cantrixil for treating ovarian cancer. GDC-0084 has been designated as an orphan drug by the U.S. Food and Drug Administration.

A portion of the proceeds is also allocated for Kazia's working capital into 2020.

Kazia Therapeutics is an oncology-focused biotechnology company developing anti-cancer drugs.